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doi:10.1016/j.jtcvs.2007.09.019bjective: Studies of high-risk pediatric cardiac transplant recipients are lacking.
he purpose of this study is to evaluate early posttransplant survival in high-risk
ediatric patients.
ethods: The United Network for Organ Sharing (UNOS) provided de-identified
atient-level data. The study population included 3502 recipients aged less than 21
ears who underwent transplantation from January 1, 1995, through December 31,
005. Recipients were stratified on the basis of the presence or absence of high-risk
riteria: pulmonary vascular resistance index greater than 6 Wood units/m2 (n 
85, 8.1%), creatinine clearance less than 40 mL/min (308, 8.8%), hepatitis C
ositivity (33, 0.9%), donor/recipient weight ratio less than 0.7 (80, 2.3%), panel
eactive antibody greater than 40% (235, 6.7%), retransplantation (235, 6.7%), and
ge less than 1 year old (840, 24.0%).
esults: Overall, 1575 (45.0%) patients met at least one high-risk criterion. Higher
umbers of high-risk criteria in a patient were correlated with increased 30-day
ortality (0 high-risk criteria: 5.2%; 1 criterion: 7.9%; 2 criteria: 12.9%; and 3 or
ore criteria: 25.0%; P  .0001) and poor long-term survival (P  .0001). Among
atients with high-risk criteria, a simplified scoring scale accurately predicts both
0-day and contingent 1-year mortality (P  .0001).
onclusions: Individually, the effect of high-risk criteria on posttransplant survival
aried; however, increasing numbers of criteria in a patient resulted in a cumulative
ncrease in mortality. A scoring scale allows for the prediction of approximate
ortality rates after transplantation. These findings suggest that recipient criteria for
ransplantation should focus on the number of high-risk criteria as well as clinical
tatus, rather than the presence or absence of a single risk factor.
ptimal allocation of the limited—and decreasing1—supply of pediatri
donor hearts requires accurate pretransplant assessment of survival and
data-derived selection of criteria indicating high risk. Unfortunately, crite-
ia for transplant eligibility remain largely the result of consensus opinion.
In the adult population, continued improvements in posttransplant outcomes (as
ell as the ongoing shortage of donor organs) have prompted attempts to expand the
ools of both donors and recipients. Results from the use of such “alternate-list”
trategies have been variable. Some authors have reported results equivalent to those
n standard criteria receipients,2 whereas others have had less success.3 In some
ases, specific traditional high-risk criteria (HRC) have failed to consistently predict
oor posttransplant outcome (older age,4-6 recipient hepatitis C positivity7), whereas
thers clearly increase posttransplant mortality (elevated pulmonary vascular resis-
ance [PVR]8).
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1
TXThe applicability of any of these data to pediatric recip-
ents is unclear. Although less well studied in children,
ome results suggest that pediatric HRC recipients have
cceptable outcomes and that our criteria remain too
trict.9,10 Evidence-based estimates of posttransplant su-
ival in a pediatric population would allow for better strat-
fication of potential recipients and optimization of trans-
lant selection criteria.
This report uses data from the United Network for Organ
haring (UNOS) database to assess posttransplant outcomes
n patients meeting traditional HRC. Our goals were (1) to
stimate the impact of HRC on posttransplant outcomes and
2) to develop a simplified scoring system to predict short-
erm posttransplant survival.
ethods
ata Collection
NOS provided de-identified patient level data from the Thoracic
egistry (data source #021606-4). Use of these data is consistent
ith the regulations of our university’s institutional review board.
ecords with incomplete data were excluded from analyses requir-
ng those data points.
tudy Population
he study population consists of 3502 transplants performed on
atients less than 21 years of age between January 1, 1995, and
ecember 31, 2005. Recipients were stratified on the basis of the
resence or absence of traditional HRC: PVR index greater than 6
ood units/m2 (n 285, 8.1%), creatinine clearance (CrCl) less than
0 mL/min (308, 8.8%), hepatitis C positivity (33, 0.9%), donor/
ecipient weight ratio less than 0.7 (80, 2.3%), panel reactive antibody
reater than 40% (235, 6.7%), retransplantation (235, 6.7%), and age
ess than 1 year old (840, 24.0%). These criteria were established
efore data analysis and are based on internal criteria for transplan-
ation at our institution, as well as a review of published rep11
ongenital heart disease (CHD) was not considered as one of the
RC because previous work had suggested that it is complex rather
han any CHD which indicated elevated risk,9 and the UNOS data-
ase does not contain detailed data regarding the CHD diagnosis that
ould enable such stratification. In addition, patients were grouped by
he number of HRC present: one (n  1189, 34.0%), two (n  334,
.5%), and three or more (n  52, 1.5%) Overall, 1575 (45.0%)
atients met at least one HRC.
ata Analysis
ata were analyzed by SAS 9.13 for Windows software (SAS Insti-
ute, Inc, Cary, NC). The primary outcomes were 30-day and contin-
ent (on 30-day survival) 1-year mortality; other outcomes included
ong-term survival (time to death) and in-hospital complications. All
ariables analyzed are available in Table E1; only significant vari
re reported. Continuous variables are reported as means  standard
eviation and were compared by the Student t test (with Bonferroni
orrection). Ordinal variables were compared by the 2 test. All P
alues are 2-sided. Multivariate regression (stepwise, P  .05) was
lso performed. Kaplan–Meier analysis and Cox proportional hazards
egression (stepwise, P  .05) were used for time-to-event analysis; i
48 The Journal of Thoracic and Cardiovascular Surgery ● Januatients without accurate follow-up times were excluded from these
nalyses. Risk, odds (OR), and hazard ratios are reported with 95%
onfidence intervals (95% CI) in parentheses. Simplified predictive
cores were developed for both 30-day and contingent 1-year mor-
ality. Data from both multivariate and univariate analysis were used
o assign points on the basis of the presence of specific comorbidities.
he predictive value of the scores was assessed by the 2 test and
ogistic regression.
esults
aseline demographics are given in Table 1 with a com
son of HRC versus normal-risk recipients; patients in the
RC group required higher levels of support and critical
edical care before transplantation.
arly and Late Mortality
hirty-day (9.2% vs 5.2%; P .0001) and contingent 1-year
ortality (10.2% vs 7.7%; P  .0229) were higher in patients
ith HRC than in those without. Within the HRC group,
ndicators of clinical support (hospitalization, mechanical ven-
ilation) were the most significant predictors of 30-day and
ontingent 1-year mortality (Table 2). Patients undergo
etransplantation and those with elevated panel reactive anti-
ody or PVR index did not have an increased risk of early
ortality (Table 2), whereas those with renal failure did 
.01, 95% CI 2.05–4.43). Small sample sizes limited the
nalysis of hepatitis C positivity (n  33, OR 1.72, 95% CI
.65–4.52) and low donor/recipient weight ratio (n  80, OR
.77, 95% CI 0.94–3.36). Later year of transplantation was
ssociated with increased survival at 30 days (P  .0069). In
ultivariate analysis, similar factors were important in predict-
ng poor short-term outcomes (Table 3).
n-hospital Complications
arly survival was drastically reduced in HRC patients
aving postoperative complications. Patients requiring dial-
sis had significantly higher 30-day (28.0% vs 5.2%) (OR
.10, 95% CI 5.13–9.81) and contingent 1-year mortality
38.4% vs 7.2%) (OR 8.04, 95% CI 5.52–11.71). Less
evere increases in 30-day (10.7% vs 5.4%) (OR 2.10, 95%
I 1.59–2.79) and contingent 1-year mortality (17.4% vs
.3%) (OR 3.14, 95% CI 2.38–4.16) occurred in patients
ith postoperative infections.
Multivariate predictors of the need for postoperative
ialysis in HRC patients included preoperative CrCl less
han 40 mL/min (OR 4.03, 95% CI 2.54–6.42), redo trans-
lantation (OR 2.32, 95% CI 1.28–4.18), and the need for
echanical ventilation (OR 2.54, 95% CI 1.57–4.09); age
ess than 1 year was protective (OR 0.56, 95% CI 0.34–
.94). Infections occurred with greater frequency in patients
ith poor pretransplant clinical status as indicated by CrCl
ess than 40 mL/min (OR 1.44, 95% CI 1.02–2.03), the need
or mechanical ventilation (OR 2.47, 95% CI 1.74–3.50),
ntensive care support (OR 1.59, 95% CI 1.11–2.26), as well
ary 2008
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TXs in younger patients between 2 and 5 years old (OR 1.55,
5% CI 1.06–2.26) and those with CHD (OR 1.38, 95% CI
.03–1.86).
mpact of Multiple HRC
n increasing number of HRC present in a single patient
esulted in cumulative higher mortality, particularly within
he first year (Figure 1). Cox regression analysis of pa
ithin the HRC group demonstrated that the need for ex-
racorporeal membrane oxygenation (ECMO) (hazard ratio
.26, 95% CI 1.60–3.18), CrCl less than 40 mL/min (hazard
atio 1.73, 95% CI 1.37–2.20), the presence of three or more
RC (hazard ratio 2.05, 95% CI 1.33–3.17), and age be-
ween 13 and 18 years old (hazard ratio 1.59, 95% CI
.18–2.14) were all associated with poor long-term
urvival.
redicting Survival in High-risk Candidates
ignificant univariate and multivariate predictors of mortal-
ty at 30 days and 1 year were used to construct a predictive
core with points awarded on the basis of the OR for
ABLE 1. Baseline demographics*
ariable Overall (n  3502)
ender (male) 1987 (56.7%)
ge
0–1 y 1092 (24.0%)
2–5 y 703 (20.1%)
6–12 y 677 (19.3%)
13–18 y 934 (26.7%)
19–21 y 348 (9.9%)
SA  1.00 m2 1811 (53.2%)
tiology of heart failure
CHD 1427 (40.8%)
Dilated cardiomyopathy 1483 (42.4%)
Hypertrophic cardiomyopathy 82 (2.3%)
edical history
Previous cardiac operation 652 (48.5%)
History of stroke 108 (3.1%)
upport at transplantation
Inotropes 1809 (51.7%)
Transfusion since listing 989 (31.9%)
Hospitalized 2328 (66.7%)
In intensive care unit 1900 (54.5%)
Mechanical ventilation 592 (16.9%)
echanical circulatory support
Any type 519 (14.8%)
Intra-aortic balloon pump 43 (1.2%)
ECMO 186 (5.3%)
Ventricular assist device 316 (9.0%)
SA, Body surface area; CHD, congenital heart disease; ECMO, extracorpo
o incomplete data entry. Numbers in parentheses reflect prevalence of portality associated with each predictor (Table 4) (seep
The Journal of Thoracics
ppendix E1 for details of score construction). The most
ccurate predictive score based on receiver operating char-
cteristic curves (Figure E1) is shown. Higher risk sc
ere associated with an increasing risk of both 30-day and
verall (noncontingent) 1-year mortality (P  .0001) (Fig-
re 2). Evaluation of the mortality associated with 
core demonstrated three categories of risk: low, moderate,
nd high. Overall 30-day and 1-year mortality for each risk
ategory are shown in Figure 3.
iscussion
llocation of the limited number of pediatric cardiac
llografts remains controversial: should an available or-
an be given to the patient most likely to die without the
ransplant or the one most likely to survive after trans-
lantation? Alternate lists for transplantation might pro-
ide a system for maximizing the equitability of the
aiting list, but providing marginal organs for the sickest
atients may worsen the problem. Therefore, optimiza-
ion of organ allocation requires accurate assessments of
Standard vs high-risk group
Standard (n  1927) High risk (n  1575) P value
1106 (57.4%) 881 (55.9%) .3862
0 (0.0%) 840 (53.3%) .0001
465 (24.1%) 238 (15.1%) .0001
468 (24.3%) 209 (13.2%) .0001
720 (37.4%) 214 (13.6%) .0001
274 (14.2%) 74 (4.7%) .0001
656 (35.1%) 1155 (75.3%) .0001
657 (34.1%) 770 (48.9%) .0001
1014 (52.6%) 469 (29.8%) .0001
58 (3.0%) 24 (1.5%) .0038
346 (46.6%) 306 (50.8%) .1255
60 (3.2%) 48 (3.0%) .8580
971 (50.4%) 838 (53.2%) .0970
388 (22.8%) 601 (42.9%) .0001
1189 (62.0%) 1139 (72.5%) .0001
913 (4.6%) 987 (62.8%) .0001
191 (9.9%) 401 (25.5%) .0001
311 (16.1%) 208 (13.2%) .0151
26 (1.4%) 17 (1.1%) .4706
78 (4.1%) 108 (6.9%) .0002
221 (11.5%) 95 (6.0%) .0001
embrane oxygenation. *Total number of patients varies for each row due
e response among those in whom the variable was entered.real mosttransplant survival and accurate delineation of a
and Cardiovascular Surgery ● Volume 135, Number 1 149
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1
TXigh-risk group unsuitable for transplantation with stan-
ard risk donor organs.
In adults, alternate-list strategies have resulted in accept-
ble outcomes with suboptimal donor organs, including
imilar rates of primary graft dysfunction12 and only
lightly decreased survival13 compared with standard recip-
ent/donor pairs. Expansion of such policies to the pediatric
opulation may result in a more optimal distribution of
rgans. The present study analyzes a set of traditional HRC
ABLE 2. Univariate predictors of 30-day and contingent 1
isk factor
Thirty-da
OR 95%
igh-risk criteria
Renal failure (CrCl  40 mL/min) 3.01 2.05–
Donor/recipient weight ratio  0.7 1.77 0.94–
Hepatitis C 1.72 0.65–
Infant (1 year old) 1.35 0.96–
Elevated PRA 1.09 0.69–
Retransplantation 0.81 0.49–
Elevated PVR (6 Wood units) 0.74 0.37–
o. of high-risk criteria
1 0.51 0.36–
2 1.57 1.07–
3 3.37 1.76–
tiology of heart failure
CHD 1.98 1.40–
Dilated cardiomyopathy 0.40 0.25–
upport at transplantation
ECMO 3.86 2.42–
Mechanical ventilation 2.05 1.45–
Intensive care unit 1.91 1.30–
Hospitalization 1.74 1.13–
Transfusion since listing 1.68 1.17–
Intra-aortic balloon pump 0.59 0.08–
retransplant medical history
Previous cardiac surgery 2.12 1.18–
Stroke 1.65 0.73–
schemic time  4 h 1.59 1.11–
ge 6–12 y 0.39 0.20–
R, Odds ratio; CI, confidence interval; CrCl, creatinine clearance; PRA, pan
isease; ECMO, extracorporeal membrane oxygenation. *Significant at P
ABLE 3. Multivariate predictors of 30-day and contingent
Thirty-day m
OR 95% CI
CMO 3.94 2.26–6.8
enal failure (CrCl  40 mL/min) 2.48 1.61–3.8
o. of HRC  3 2.42 1.09–5.3
HD 1.64 1.08–2.4
ear of transplant 0.91 0.85–0.9
R, Odds ratio; CI, confidence interval; ECMO, extracorporeal membrane o
eart disease.
50 The Journal of Thoracic and Cardiovascular Surgery ● Januo examine their impact on early mortality after cardiac
ransplantation in a pediatric population and to develop a
ore accurate pretransplant assignment of patients to post-
ransplant risk groups.
re HRC Truly High Risk?
e found that several criteria traditionally used to identify
high-risk” patients had poor correlation with early trans-
lant mortality. Elevated PVR index was not associated
r mortality within the high-risk recipients
tality Contingent 1-year mortality
P value OR 95% CI P value
.0001* 2.28 1.47–3.53 .0002*
.0754 0.94 0.40–2.23 .8856
.2657 1.88 0.63–5.63 .2499
.0853 1.05 0.72–1.52 .8117
.7058 0.79 0.44–1.41 .4205
.4153 0.81 0.46–1.42 .4563
.3934 1.01 0.52–1.95 .9761
.0001* 0.76 0.50–1.15 .1933
.0188* 1.31 0.85–2.03 .2257
.0001* 1.22 0.42–3.53 .7116
.0001* 1.70 1.16–2.50 .0058*
.0001* 0.53 0.33–0.84 .0060*
.0001* 2.14 1.11–4.14 .0202*
.0001* 1.86 1.25–2.77 .0020*
.0008* 1.69 1.12–2.54 .0119*
.0105* 1.79 1.13–2.86 .0126*
.0046* 2.06 1.37–3.10 .0004*
.6071 3.00 0.95–9.45 .0489*
.0105* 2.84 1.45–5.55 .0016*
.2231 3.05 1.34–6.96 .0053*
.0115* 1.34 0.90–1.99 .1490
.0058* 0.69 0.38–1.26 .2253
ctive antibody; PVR, pulmonary vascular resistance; CHD, congenital heart
5 level.
ar mortality within the high-risk recipients
ity Contingent 1-year mortality
P value OR 95% CI P value
.0001 2.10 1.04–4.26 .0387
.0001 2.11 1.35–3.29 .0010
.0302
.0207 1.68 1.10–2.57 .0158
.0036
ation; CrCl, creatinine clearance; HRC, high-risk criteria; CHD, congenital-yea
y mor
CI
4.43
3.36
4.52
1.90
1.73
1.34
1.48
0.72
2.28
6.47
2.81
0.63
6.16
2.91
2.82
2.66
2.40
4.48
3.82
3.76
2.29
0.78
el rea1-ye
ortal
6
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6
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7
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TXith decreased survival. This is consonant with other stud-
es that have demonstrated the impact of elevated PVR on
ight ventricular dysfunction, but not on survival.14,15 It is
ikely that current management of right-sided heart dysfunc-
ion, including nitric oxide, has largely mitigated its impact
n survival.14-17 Although this analysis demonstrates a s-
ival advantage to patients with elevated PVR index as well
s those undergoing retransplantation, it should be empha-
ized that this is true in comparison with the high-risk
atients and likely reflects a survival in these populations
quivalent to the standard risk patients.
Similar negative results were obtained with several other
easures of “high-risk” transplant recipients, although the
Figure 1. Five-year Kaplan–Meier survival estimates a
high-risk criteria (HRC) present at the time of transpla
ABLE 4. Risk factor summation score
isk factor
Thirty-day morta
OR P
CMO 3.9 
o. of HRC  3 2.4
eoperation* 2.1
troke* 1.7
enal failure (CrCl  40 mL/min) 2.5 
HD 1.6
echanical ventilation* 2.0 
ntensive care unit* 1.9
R, Odds ratio; ECMO, extracorporeal membrane oxygenation; HRC, h
Weighting based on odds ratio from univariate analysis; see Appendix E1.
The Journal of Thoracicvaluation of hepatitis C positivity and low donor/recipient
eight ratio as risk factors is constrained by the small
ample sizes in those populations.
Pretransplant renal failure (CrCl less than 40 mL/min)
as the only risk factor consistently predictive of poor
ostoperative survival; the outcomes of patients requiring
ialysis (an 8-fold increase in 1-year mortality) reinforce the
elationship between renal function and survival. In young
atients without intrinsic kidney disease, renal failure may
imply act as a surrogate of poorly compensated heart
ailure. Therefore, these patients should benefit from early
echanical circulatory support and optimization of sys-
emic perfusion.
ustrated as a function of the presence and number of
on. (P < .0001, Wilcoxon test.)
Contingent 1-year mortality
Weightinge OR P value
1 2.1 .0387 4
2 1.2 .7116 3
5 2.8 .0016 2
1 3.1 .0053 2
1 2.1 .0001 2
8 1.7 .0158 1
1 1.9 .0020 1
8 1.7 .0119 1
k criteria; CrCl, creatinine clearance, CHD, congenital heart disease.re ill
ntatility
valu
.000
.030
.010
.223
.000
.020
.000
.000
igh-risand Cardiovascular Surgery ● Volume 135, Number 1 151
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1
TXBecause of the usual lack of intrinsic renal disease and
he possibility of return of renal function, some have
rgued that simultaneous renal transplants should be
voided in children.17 However, combined transplant
ave acceptable outcomes in adults and appear to de-
rease the risk of allograft rejection.18,19 Furthermore,
imultaneous heart/kidney transplantation may confer a
urvival advantage over heart transplant alone in patients
ith dialysis-dependent renal failure.20 Sample sizes ar
imited, but a brief review of 24 simultaneous pediatric
Figure 2. Observed 30-day (black) and 1-year (slanted
at least one HRC (P < 0.0001).
igure 3. Thirty-day (black) and 1-year (slanted brick pattern)
ortality stratified based on risk category (low  score 0-5,soderate  6 –10, high  11–15). P < .0001.
52 The Journal of Thoracic and Cardiovascular Surgery ● Janueart/kidney transplantations reported in the UNOS data
et suggests that they have similar long-term outcomes
ith 1-year survival of 85% (unpublished data); this is
upported by case reports providing anecdotal evidence
f good long-term outcomes after simultaneous renal
ransplantation.21,22 Further analysis of simultaneou
ransplants and other therapies for pediatric patients with
retransplant renal dysfunction is warranted.17
As noted earlier, we did not include CHD among our
RC because of the perceived limitations in the UNOS
atabase with regard to congenital diagnoses. Despite these
imitations, CHD did predict poorer outcomes in this pop-
lation. Single-institution data suggests that complex CHD
ccounts for most of this additional risk.10 Further studies
ill be needed in data sets including stratification of con-
enital diagnoses to accurately elucidate the impact of CHD
n posttransplant outcomes.
mpact of Multiple HRC
lthough renal failure was the only one of the traditional
RC to be a significant predictor of early mortality, the
ccumulation of HRC in a single patient resulted in a
ignificant decrement in early survival. This phenomenon
as not previously been described and suggests that cri-
eria for transplantation should include the number of
RC rather than simply the presence or absence of a
pattern) mortality for each risk score in patients withbrickingle risk factor.
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TXlinical Status Before Transplant
n this analysis, as in previous reports, indicators of pre-
ransplant clinical status remain the most significant predic-
ors of poor outcomes. Consistent with previous reports,10,23
he need for ECMO was a strong negative predictor of both
0-day and contingent 1-year mortality. The need for hos-
italization, especially in the intensive care unit and with
echanical ventilation, was associated with poor outcomes.
his (particularly given the negative effects of preoperative
r postoperative renal failure) reinforces the need to attempt
ransplantation before patients becoming critically ill and—
here not possible—to attempt aggressive resuscitation
ith mechanical ventricular support (rather than ECMO) to
mprove end-organ function, wean patients from the venti-
ator, and optimize their clinical condition.
creening Score for HRC Patients
he development of a simplified screening score for pedi-
tric patients meeting traditional HRC should provide im-
ortant prognostic information to physicians, patients, and
amilies as they contemplate transplantation. The scoring
ystem presented here divides patients into three risk
roups, with an approximate doubling of mortality between
roups: those with scores of 0 to 4 are at low risk (1-year
ortality 15%), those with scores from 5 to 9 are at
oderate risk (1-year mortality 30%), and those with
cores of 10 or more are at high risk (1-year mortality
62%). Although this score applies specifically to patients
n the traditional HRC group, further evaluation may enable
ts applicability to be broadened to a larger cross-section of
atients.
Validation of the score may enable its use in accurately
tratifying patients into standard and alternate-list recipi-
nts. Finally, clinical therapies may be directed at correcting
onditions known to predispose to poor outcomes (mechan-
cal ventilation, renal failure, use of ECMO) before
ransplantation.
imitations
hese data have several limitations. First, there are prob-
ems inherent to the UNOS data set: incomplete data entry
nd variability between reporting centers as to which pre-
ransplant hemodynamic and clinical variables are reported.
econd, although the data analysis supports associations
etween variables and outcomes, causal relationships can-
ot be determined. Many of the risk factors may simply be
arkers for poor clinical status before transplantation rather
han a direct causal factor in poor survival. Finally, the
coring system we describe here remains to be validated,
nd further study is required to confirm its accuracy in
redicting early posttransplant outcomes. In addition, it
pplies specifically to patients within the HRC group and its
The Journal of Thoracicpplicability to standard risk recipients remains to be
etermined.
onclusions
n summary, we have reviewed the UNOS thoracic organ
ransplant registry and examined the outcomes of patients
istorically considered at high risk for early transplant mor-
ality. We have found that several of these HRC do not
redict poor outcomes but that the cumulative effect of
ultiple criteria in a single patient results in poor survival.
inally, we have described a simplified screening score to
dentify the patients within the HRC population most and
east likely to survive transplantation. This forms an initial
ttempt to accurate stratify patients before transplantation.
urther efforts are required to optimally allocate the limited
upply of donor organs.
We thank UNOS for supplying these data and Katarina Ander-
on for her assistance with our analysis.
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iscussion
avid N. Campbell (Denver, Colo). Obviously you and your
oauthors have put a lot of work and effort into this very impres-
ive study, which does cover a large number of pediatric and
oung adults. We actually use 18 and under for pediatric age, so
here are some young adults in this “pediatric” group, but 3500
atients is an impressive number of patients over a decade between
995 and 2005. These were all transplanted and then entered into
he UNOS database. Again, this consists of a great deal of time and
ffort to get this information. I have two comments and then two
uestions.
As you pointed out well in the manuscript, in pediatric heart
ransplant recipients, PVR is not an identifier for poor outcome and
oor survival as it is in adults. This is something that gets lost
ometimes in the pediatric patient group.
You have re-emphasized that the predictors of pretransplant
linical status remain a significant predictor of poor outcomes and,
s you have pointed out, these are hospitalization, intensive care
nit care, mechanical ventilation, and particularly ECMO support.
ll of these portend a very poor outcome. h
54 The Journal of Thoracic and Cardiovascular Surgery ● JanuI think the message to be taken from this is that earlier inter-
ention in the pediatric group is warranted, and we are far behind
he adults in terms of using ventricular assist devices. I know
olumbia, particularly, is a large user of those, and I know that you
ave already set out a scale very much like you have used for this
ediatric group. I think it is very important that the pediatric heart
ransplant surgeons begin to use mechanical assist devices much
arlier. We are obviously coming onto that scene later than we
hould be. Part is because we do not have good ventricular assist
evices in children, but they are being developed and ideally by
009, with the money that is being put into five programs, we will
ave some information and better devices.
My first question to you is, have you actually used this scoring
ystem in any patients to predict outcome, or is this just a scale that
ou have somewhat arbitrarily determined and are planning on
sing?
Dr Davies. We have not used it yet. We have developed the
core recently and are in the early stages of planning to use it.
mportantly, the score needs to be validated before we can use it
xtensively. This presents a challenge because the UNOS data
nclude all patients who have undergone transplantation in the
nited States, so it is harder to find patients who are not contained
n the database. Our current thinking is to use some Canadian data
o validate it, as one of our coauthors is at the University of
oronto. Before that, our intention is to use it as a guide, especially
o attempt to reduce the particularly high risk associated with
actors like ECMO. The score reinforces the need to wean children
rom ECMO before transplantation if at all possible. Therefore, at
his time, the score is important both to help with prognostication
nd discussions with families and then to guide clinical therapy in
erms of getting people toward a better score before transplanta-
ion.
Dr Campbell. My second question concerns a circumstance
esembling one of the two examples that you described. We
ecently performed transplantation in a young child with exactly
he circumstances you pointed out. The child had an operation that
id not go well, ended up on ECMO for a long period of time, and
nded up undergoing transplantation, which in your group would
ortend again a poor outcome. That child actually did quite well,
o it is going to be difficult, I think, to predetermine exactly how
hese children will do. In our own institution, we were questioned
s to whether we should even have undertaken that transplant. My
uestion to you is, what would you do with patients like that in the
uture who are on say beyond that 10 scoring in your category and
re very high risk? Would you just not transplant them? Obviously,
art of the idea would be to put them on a ventricular assist device,
ut even somebody that has been on ECMO for a period of time is
ot really a good device candidate, as you pointed out. Again, the
olumbia group has a scale that they use to determine whether to
lace devices, and I am not sure some of these patients would even
eet the criteria for that. So where do you go with those patients?
o you decide you will not attempt transplantation, or do you go
head and try?
Dr Davies. Given the lack of validation, it is difficult to say not
o transplant them. In addition, although a 50% 1-year mortality is
bviously high, the mortality for the same patient without a trans-
lant is higher. More research needs to clarify which patients will
ave the most improvement with transplantation and what the best
ary 2008
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Davies et al Cardiothoracic Transplantationethod is for optimizing the limited supply of donor organs before
e would suggest that this score should be used to exclude people
rom transplantation.
Dr John Hawkins (Salt Lake City, Utah). I just have a couple
f quick questions. How did you pick these risk criteria? How did
ou pick just seven? Maybe I do not understand the methodology,
ut why did you not include CHD or multiple previous operations
r ECMO as a risk factor in doing the modeling?
Second, have you used this clinically to turn someone down
et? In someone who has three or four or five risk factors, have you
ctually used this information in your practice?
Dr Davies. To answer your second question first, we have not
tarted using the score yet and the score needs to be validated
efore its use. We need to refine the accuracy of these data before
e can turn people down for transplantation.
With regard to our choice of risk factors, we went through
nternal Columbia criteria for separating patients who were at
tandard risk versus high risk for transplant. Most of these criteria
ere based on consensus statements or older data. In addition, we
ent through the literature and tried to identify other factors that
ight be predictive as well.
Specifically, in terms of not including CHD, our own data
uggest that patients with CHD as a whole group have similar
utcomes and that it is the patients with complex CHD who
ccount for increased risk. Unfortunately, the UNOS data set does
ot allow one to separate those patients. Therefore, as an a priori
ecision, we did not want to include it in our list of criteria. g
The Journal of Thoracicowever, it did turn out to be a reliable risk factor even in the
NOS data set, so it was included in our risk score based on
redetermined methodology. Other information provides signifi-
ant opportunity for improvement: either single institution studies
r the Pediatric Heart Transplant Study Group, which includes
uch more detailed diagnosis information that will allow us to
ease out the true contribution of CHD to posttransplant outcomes.
Dr Jonathan Chen (New York, NY). I just want to make a
omment. One big impetus for us to pursue this question at all is
hat we lag behind the adult service mainly because the numbers
re so small. We have had a lot of success in the adult arena with
n alternate list comprised of a separate group of patients with
hom we have a very stern conversation pretransplant indicating
hat they are not candidates in the routine pool but could be
andidates on the alternate list made for patients who are really
igh risk. I believe it does make clear for families and for the
atients themselves the gravity of the situation. What we did find
ust anecdotally in the adult world with the alternate list (these are
rgans that are passed over by every other program) is that about
0% of them end up being normal hearts. They just do not have the
ppropriate size to recipient available. This is particularly pertinent
or the pediatric group. As I am sure everyone knows, you will
ften get a telephone call about a young infant donor and every-
ody has passed it over because it is simply not the right size. It is
ot that these patients get “marginal hearts” and thereby stack
onor variables with recipient variables. I think it gives them a
ood shot at transplant, albeit at high risk.
and Cardiovascular Surgery ● Volume 135, Number 1 155
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TXppendix E1
ll significant multivariate predictors of 30-day mortality were
ncluded in the score. Significant univariate predictors were also
ncluded when certain criteria were met: (1) they were highly
redictive of mortality but the variable was not coded in a suffi-
ient number of patients to meet the threshold P value for entry o
55.e1 The Journal of Thoracic and Cardiovascular Surgery ● Janto the multivariate model and (2) inclusion in the scoring scale
ncreased the predictive value of the scale (measured by receiver
perating curves, c-score, and 2 tests. The score assigned to each
isk factor (given in Table 4) was based on the OR for 30-d
-year mortality and was adjusted to maximize the predictive value
f the scoring scale at both time periods.
nuary 2008
T
Y
A
W
B
E
E
E
V
E
I
A
N
N
H
I
R
P
H
R
H
H
H
P
H
L
E
P
N
G
W
D
P
C
D
A
D
D
Pulmonary vascular resistance (continuous variable)
F
(
b
a
Davies et al Cardiothoracic Transplantation
The Journal of Thoracic aigure E1. Receiver operating curves are shown for both 30-day
A) and overall 1-year survival (B) based on the scoring scale. In
oth cases, as demonstrated by the c score, the scoring scale
dequately predicts survival.ABLE E1. List of analyzed variables
ear of transplant
ge (both continuous and stratified)
eight (both continuous and stratified)
ody surface area (both continuous and stratified)
tiology: congenital heart disease
tiology: dilated cardiomyopathy
tiology: retransplant
entricular assist device at transplantation
xtracorporeal membrane oxygenation at transplantation
ntra-aortic balloon pump at transplantation
ny type of mechanical circulatory support at transplantation
eed for inotropic support at transplantation
eed for mechanical ventilation at transplantation
ospitalized at transplantation
n intensive care unit at transplantation
equirement for transfusions between listing and transplantation
ulmonary vascular resistance index  6 Wood units
istory of chronic renal failure
enal failure as indicated by creatinine clearance  40 mL/min
istory of stroke
istory of pulmonary embolus
istory of previous cardiac surgery
rolonged ischemic time (4 hours)
epatitis C positivity
ow donor/recipient weight ratio (0.7)
levated panel reactive antibodies (both  10% and  40%)
resence of high-risk criteria
umber of high-risk criteria present
ender
aiting time
ays of waiting as status 1/1A
ercentage of time waiting as status 1/1A
ardiac output before transplantation
onor age
llograft ischemic time
onor creatinine
onor/recipient weight rationd Cardiovascular Surgery ● Volume 135, Number 1 155.e2
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